Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.

doi:10.1007/BF00315282

Back to search

Article

Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.

European journal of clinical pharmacology - 1 Jan 1993

Lledó P, Abrams S M, Johnston A, Patel M, Pearson R M, Turner P

Abstract excerpt

Marked interindividual variation has been observed in the pharmacokinetics of the antiarrhythmic agent mexiletine. The fact that its urinary excretion is dependent on urinary pH may account, in part, for such variation. The influence that genetic differences in hepatic metabolism of the debrisoqu...

Topics

Adult
Debrisoquin
Female
Humans
Hydrogen-Ion Concentration
Hydroxylation
Infusions, Intravenous
Liver
Male
Mexiletine
Phenotype

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.